Redefining Tumor Profiling: An Innovative, Non-Invasive Approach to cfDNA Biomarker Integration from Plasma and Urine Using Advanced Bioinformatics

Circulating cell-free DNA (cfDNA) profiling from blood plasma has significant potential for clinical application in breast cancer. However, exploration into urinary cfDNA has been limited. In a previous pilot study of plasma-derived and matching urinary cfDNA samples obtained from 15 presurgical triple-negative breast cancer patients, we found that plasma and urine may be complementary liquid biopsy samples for molecular profiling of tumors by targeted sequencing. Here, we present insights from a further expanded study with a larger patient cohort, demonstrating the utility of urine as a key liquid biopsy sample for cfDNA biomarker identification through targeted sequencing. Comparative data from plasma samples will also be presented, highlighting how both urine and plasma can be used in tandem in cfDNA biomarker detection studies